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Abstract
Background: Cervical cancer incidence and mortality rates are high among women from Appalachia, yet data do not exist
on human papillomavirus (HPV) prevalence among these women. We examined the prevalence of genital HPV among
Appalachian women and identified correlates of HPV detection.
Methods: We report data from a case-control study conducted between January 2006 and December 2008 as part of the
Community Awareness, Resources, and Education (CARE) Project. We examined HPV prevalence among 1116 women (278
women with abnormal Pap tests at study entry [cases], 838 women with normal Pap tests [controls]) from Appalachian Ohio.
Analyses used multivariable logistic regression to identify correlates of HPV detection.
Results: The prevalence of HPV was 43.1% for any HPV type, 33.5% for high-risk HPV types, 23.4% for low-risk HPV types,
and 12.5% for vaccine-preventable HPV types. Detection of any HPV type was more common among women who were
ages 18–26 (OR = 2.09, 95% CI: 1.26–3.50), current smokers (OR = 1.86, 95% CI: 1.26–2.73), had at least five male sexual
partners during their lifetime (OR = 2.28, 95% CI: 1.56–3.33), or had multiple male sexual partners during the last year
(OR = 1.98, 95% CI: 1.25–3.14). Similar correlates were identified for detection of a high-risk HPV type.
Conclusions: HPV was prevalent among Appalachian women, with many women having a high-risk HPV type detected.
Results may help explain the high cervical cancer rates observed among Appalachian women and can help inform future
cervical cancer prevention efforts in this geographic region.
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Introduction
Human papillomavirus (HPV) is the most common sexually
transmitted infection (STI) in the United States (U.S.) [1], with
infections having the potential to cause various adverse health
outcomes. Among females, high-risk (i.e., oncogenic) HPV types,
mainly types 16 and 18, cause over 90% of cervical and anal
cancers and lower percentages of vaginal, vulvar, and oral cancers
[2]. Low-risk (i.e., nononcogenic) HPV types, mainly types 6 and
11, cause almost all anogenital warts [3]. National estimates
suggest that about 40% of females ages 14–59 are infected with at
least one HPV type and about 30% are infected with a high-risk
HPV type [4]. HPV prevalence differs across racial and ethnic
groups, with infection more common among African American
and Hispanic women [4]. The higher prevalence is likely a key
factor contributing to the higher cervical cancer incidence rates
observed among these racial and ethnic groups [5]. Thus, it
becomes important to determine HPV prevalence among popu-
lations at high-risk for cervical cancer to better understand existing
cervical cancer disparities.
A high-risk population that has not yet been examined in terms
of HPV prevalence is women living in the Appalachian region of
the U.S. Appalachia consists of the entire state of West Virginia
and portions of 12 other states that extend from New York to
Mississippi [6]. The region has a total population of about 25
million people (about 8% of the U.S. population) and is
characterized by less racial diversity and lower socioeconomic
status compared to the rest of the country [7]. Areas within
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Appalachia have among the highest cervical cancer incidence and
mortality rates in the U.S. [8]. Research comparing Appalachian
women to non-Appalachian women from the same states has
shown cervical cancer incidence and mortality rates are often
higher among the Appalachian women [9,10].
There may be several reasons for the current cervical cancer
disparities among women from Appalachia. Risky sexual behavior
that likely increases the chance of HPV infection is common
among these women [11]. Data also indicate that smoking rates
are higher among Appalachian residents compared to their non-
Appalachian counterparts from the same states [12], which is
important since smoking may prolong the duration of HPV
infections [13]. Furthermore, fewer Appalachian women receive
cervical cancer screening tests compared to non-Appalachian
women [14,15]. The current study provides the first data we are
aware of on the prevalence of HPV among women from
Appalachia, which can help our understanding of the cervical
cancer disparities among these women. This information is also
essential for developing effective educational programs and
interventions to address and reduce these disparities.
Materials and Methods
Ethics Statement
The Institutional Review Boards of The Ohio State University,
the University of Michigan, and the Centers for Disease Control
and Prevention (CDC) approved this study.
Study Design
This study was part of the Community Awareness, Resources,
and Education (CARE) Project, one of eight Centers for
Population Health and Health Disparities (P50) funded by the
National Institutes of Health (NIH). We report on one component
of the CARE Project, a case-control study that focused on the
determinants of abnormal cervical cytology among women living
in Appalachian Ohio. A secondary aim of this study was to
examine HPV prevalence among these women, the focus of this
report. Appalachian Ohio is a 32 county region (29 at the time of
this study) located in the southern and eastern sections of Ohio.
Cervical cancer incidence and mortality rates are 12% and 21%
higher, respectively, in Appalachian Ohio counties compared to
the non-Appalachian counties in Ohio [10]. We conducted the
current study between January 2006 and December 2008. Data
from the CARE Project are available upon request.







40 or older 358 (32.2)
Race/ethnicity
Non-Hispanic white 1038 (93.9)
Other 67 (6.1)
Marital status
Never married 362 (33.3)
Divorced/widowed/separated 199 (18.3)
Married/member of a couple 526 (48.4)
Education
Less than a high school degree 131 (11.8)
High school degree 408 (36.7)
More than a high school degree 572 (51.5)
Annual household income
$20,000 or less 477 (50.7)
$20,001–$50,000 297 (31.6)
More than $50,000 166 (17.7)
Health Characteristics
Smoking status
Never smoker 471 (42.6)
Former smoker 167 (15.1)




Pap test within the last 3 years
No 161 (14.5)
Yes 949 (85.5)
Ever have prior abnormal Pap test
No 620 (56.1)
Yes 486 (43.9)
Pap test result upon entry into CARE Project
Normal (control) 838 (75.1)
Abnormal (case) 278 (24.9)
Ever told they had HPV infection (venereal warts,
condylomas, or a papillomavirus infection)
No 974 (88.5)
Yes 126 (11.5)
Age at first sexual intercourse
15 or younger 350 (32.2)
16 or older 736 (67.8)
Number of male sexual partners during lifetime
4 or fewer 458 (44.9)
5 or more 561 (55.1)




2 or more 220 (20.5)
Any male sexual partners with history of STI
No/don’t know 952 (89.2)
Yes 115 (10.8)
Number of female sexual partners during lifetime
0 1042 (95.2)
1 or more 53 (4.8)
Note. Totals may be less than stated sample size due to missing data. Percents
may not sum to 100% due to rounding. CARE = Community Awareness
Resources Education, HPV = human papillomavirus, STI = sexually transmitted
infection.
doi:10.1371/journal.pone.0074276.t001
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Women included in this study were from 17 participating health
clinics located throughout the Appalachian Ohio region. Women
were eligible to participate if they were: 1) age 18 or older; 2) a
resident of an Appalachian Ohio county; 3) had an intact uterine
cervix and corpus; 4) were not pregnant; 5) did not have a history
of cervical cancer; and 6) provided written informed consent.
Women scheduled for a routine Papanicolaou (Pap) test on a day
that a study nurse was at one of 17 clinics were asked to participate
in the study. Women completed a self-administered questionnaire
following consent and prior to undergoing their Pap test. During
the visit, the provider took an additional research cytology sample
and obtained a cervical sample in specimen transport medium
(STM; Qiagen Inc., Valencia, CA) for HPV testing.
Women with abnormal cervical cytology at study entry were
considered cases for the case-control study that aimed to identify
the determinants of abnormal cervical cytology. Women were
classified as having abnormal cervical cytology according to the
2001 Bethesda System for Reporting Pap Smear Results [16].
Using this system, cases were classified as having atypical
squamous cells of undetermined significance (ASC-US), atypical
squamous cells cannot exclude HSIL (ASC-H), atypical glandular
cells (AGC), low-grade squamous intraepithelial lesions (LSIL),
high-grade squamous intraepithelial lesions (HSIL), adenocarci-
noma in situ (AIS), or carcinoma. We randomly selected three
women with normal cervical cytology at study entry from the same
clinic within a three-month window around the date of the case’s
abnormal cervical cytology to serve as controls. This part of the
CARE Project had a participation rate of 70% [17], with a total of
1131 women included in the case-control study. We report data on
1116 women (278 cases, 838 controls), excluding 15 women with
inadequate HPV results.
HPV Detection
The STM sample was stored at –70uC until shipped to the
Centers for Disease Control and Prevention (CDC). At CDC, the
samples were thawed and 150 mL of the 1.0 mL sample were
extracted with the MagNA Pure DNA kit III (Roche Applied
Science, Indianapolis, IN), with 10 mL of extract used in the
Research Use Only (RUO) Linear Array (LA) HPV Genotyping
Test (Roche Diagnostics, Indianapolis, IN). The LA assay detects
37 HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52,
53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81,
82, 83, 84, 89, and IS39) and includes ß-globin as an endogenous
positive control. Samples positive for the XR probe on the LA
HPV strip that were also positive for HPV 33, 35, and 58 were
tested with an HPV 52 quantitative PCR assay to confirm or
exclude the presence of HPV 52 [18]. Samples negative for both
ß-globin and HPV were considered inadequate for interpretation
and omitted from analyses.
Based on HPV testing results, we examined detection of: 1) any
HPV type; 2) a high-risk HPV type (16, 18, 26, 31, 33, 35, 39, 45,
51, 52, 53, 56, 58, 59, 64, 66, 67, 68, 69, 70, 73, 82, or IS39); 3) a
low-risk HPV type (6, 11, 40, 42, 54, 55, 61, 62, 71, 72, 81, 83, 84,
or 89); and 4) a vaccine-preventable HPV type (i.e., a type
included in the quadrivalent HPV vaccine [19]: type 6, 11, 16, or
18). We used the same high- and low-risk classification scheme as a
recent national study that analyzed data from the National Health
and Nutrition Examination Survey (NHANES) [4] in order to
facilitate comparisons between data from the CARE Project and
the NHANES. For descriptive purposes, we also examined the
detection of high-risk HPV types using a classification scheme
from the International Agency for Research on Cancer (IARC)(-
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68; Groups
1 and 2A of the IARC scheme)[20]. Lastly, we examined the
detection of each individual HPV type and detection of multiple
HPV types (i.e., women testing positive for two or more HPV
types). We do not, however, report detailed data on multiple-type
HPV infections (e.g., HPV types present in the multiple-type
infections). We feel such detailed data are beyond the scope of this
manuscript, but the data will be considered for a future
publication.
Measures
We collected data on a wide range of health-related and
demographic characteristics and examined them as potential
correlates of HPV detection (Table 1). Data on potential correlates
were obtained during the self-administered questionnaire that
women completed prior to undergoing their cervical cancer
screening test upon study entry.
We examined women’s smoking status (never smoker, former
smoker, or current smoker) and whether they had ever been
pregnant. We collected information on women’s cervical cancer
screening histories and determined if they had a Pap test within
the three years prior to study entry and whether they ever had a
previous abnormal Pap test. Women indicated if they had ever
been told by a doctor that they had an HPV infection (described to
women as venereal warts, condylomas, or a papillomavirus
infection). Women also indicated their age at first sexual
intercourse, number of male sexual partners during their lifetime,
number of male sexual partners within the last year, if any of their
male partners had been diagnosed with an STI, and if they had
any female sexual partners during their lifetime. We collected data
on several demographic characteristics, including age, race/
ethnicity, marital status, education, and annual household income.
Table 2. HPV prevalence among women from the CARE Project and the NHANES.
CARE – All women CARE – Controls CARE – Cases NHANESa
(n = 1116) (n = 838) (n = 278)
Any HPV 43.1 (40.2–46.0) 32.1 (28.9–35.3) 76.3 (71.3–81.3) 39.2 (37.0–41.4)
High-risk HPVb 33.5 (30.7–36.3) 21.5 (18.7–24.3) 69.8 (64.4–75.2) 26.9 (24.7–29.1)
Low-risk HPVc 23.4 (20.9–25.9) 17.4 (14.8–20.0) 41.4 (35.6–47.2) 26.1 (24.0–28.2)
Note. Table reports percents and 95% confidence intervals in parentheses. HPV = human papillomavirus, CARE = Community Awareness Resources Education,
NHANES = National Health and Nutrition Examination Survey.
aEstimates from the NHANES are for non-Hispanic white women [4], since 93.9% of women from the CARE Project were non-Hispanic white.
bIncluded HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 64, 66, 67, 68, 69, 70, 73, 82, and IS39 [4].
cIncluded HPV types 6, 11, 40, 42, 54, 55, 61, 62, 71, 72, 81, 83, 84, and 89 [4].
doi:10.1371/journal.pone.0074276.t002
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Age was categorized as 18–26 years old (within the recommended
age range for HPV vaccination [19]), 27–39 years old, and 40
years or older.
Statistical Analysis
We first calculated descriptive statistics in examining the
prevalence of HPV among participants. We then used logistic
regression to identify correlates of two outcomes: detection of any
HPV type and detection of a high-risk HPV type (using the same
classification scheme for high-risk HPV types as a recent study that
analyzed data from the NHANES) [4]). For each outcome, we
entered statistically significant univariable correlates (p,0.05) into
a multivariable logistic regression model. Adjusted odds ratios
(ORs) and 95% confidence intervals (CIs) were obtained from
these multivariable logistic regression models. All logistic regres-
sion models included health clinic as a random effect since women
were clustered within health clinics. Data were analyzed using SAS
Version 9.2 (SAS Institute Inc., Cary, NC) and all statistical tests
were two-tailed, using a critical value of a= 0.05.
Results
Participant Characteristics
Most women were less than 40 years old (67.8%), non-Hispanic
white (93.9%), had at least a high school degree (88.2%), and
reported a household income of $50,000 or less (82.3%)(Table 1).
Less than half of women were married or a member of a couple
(48.4%) and about a third indicated that they had never been
married (33.3%). Over 40% of women (42.4%) were current
smokers with an additional 15.1% being former smokers. A
majority of women (85.5%) reported receiving a Pap test in the
three years prior to study enrollment. Although 43.9% of women
reported a history of at least one prior abnormal Pap test, only
11.5% indicated that a doctor had ever told them they had
venereal warts, condylomas, or a papillomavirus infection. Most
women reported they were age 16 or older at the time of their first
sexual intercourse (67.8%) and just over half (55.1%) reported
having at least five male sexual partners during their lifetime.
Among women with an abnormal Pap test upon entry into the
CARE Project (i.e., cases; n = 278), 143 (51.4%) had ASC-US, 7
(2.5%) had AGC, 112 (40.3%) had LSIL, 15 (5.4%) had HSIL,
and 1 (0.4%) had squamous cell carcinoma.
HPV Prevalence
The overall prevalence of any HPV type, as measured by HPV
DNA detection in the LA assay, was 43.1% (Table 2). Using the
same classification scheme as a recent study that analyzed data
from the NHANES [4], a high-risk HPV type was detected in
33.5% of women while a low-risk HPV type as detected in 23.4%
of women. Using the classification scheme from IARC [20], a
high-risk HPV type was detected in 27.9% of women. A vaccine-
preventable HPV type (6, 11, 16, or 18) was detected in 12.5% of
women, including 21.0% of women ages 18–26. Among all
women, HPV type-specific prevalence ranged from 0.0% to 8.2%
(Table 3). The most prevalent HPV types included types 16
(8.2%), 53 (5.7%), 62 (4.8%), 51 (4.7%), 84 (4.6%), 89 (4.5%), 66
(4.3%), and 39 (4.1%). All other HPV types had a prevalence of
less than 4.0%, including types 18 (2.7%), 6 (2.2%), and 11 (0.3%).
Over 20% of women (22.4%) had two or more HPV types
detected.
Correlates of HPV Detection
In multivariable analyses, detection of any HPV type was more
common among women ages 18-26 compared to women ages 40
or older (OR = 2.09, 95% CI: 1.26–3.50)(Table 4). Current
smokers were more likely to be HPV-positive compared to never
smokers (OR = 1.86, 95% CI: 1.26–2.73). Detection of any HPV
type was also more common among women with an abnormal Pap
Table 3. Prevalence of HPV types among women from the
CARE Project.
HPV type Riska All women Controls Cases
(n = 1116) (n = 838) (n = 278)
16 High 92 (8.2) 41 (4.9) 51 (18.3)
53 High 64 (5.7) 29 (3.5) 35 (12.6)
62 Low 53 (4.8) 21 (2.5) 32 (11.5)
51 High 52 (4.7) 18 (2.2) 34 (12.2)
84 Low 51 (4.6) 29 (3.5) 22 (7.9)
89 Low 50 (4.5) 22 (2.6) 28 (10.1)
66 High 48 (4.3) 19 (2.3) 29 (10.4)
39 High 46 (4.1) 18 (2.2) 28 (10.1)
54 Low 43 (3.9) 25 (3.0) 18 (6.5)
52 High 38 (3.4) 16 (1.9) 22 (7.9)
31 High 35 (3.1) 15 (1.8) 20 (7.2)
56 High 34 (3.1) 14 (1.7) 20 (7.2)
42 Low 31 (2.8) 17 (2.0) 14 (5.0)
59 High 31 (2.8) 13 (1.6) 18 (6.5)
18 High 30 (2.7) 13 (1.6) 17 (6.1)
61 Low 25 (2.2) 13 (1.6) 12 (4.3)
6 Low 24 (2.2) 10 (1.2) 14 (5.0)
45 High 22 (2.0) 9 (1.1) 13 (4.7)
67 High 22 (2.0) 13 (1.6) 9 (3.2)
83 Low 22 (2.0) 9 (1.1) 13 (4.7)
70 High 21 (1.9) 13 (1.6) 8 (2.9)
55 Low 19 (1.7) 10 (1.2) 9 (3.2)
35 High 18 (1.6) 11 (1.3) 7 (2.5)
58 High 18 (1.6) 9 (1.1) 9 (3.2)
68 High 18 (1.6) 8 (1.0) 10 (3.6)
73 High 18 (1.6) 7 (0.8) 11 (4.0)
40 Low 14 (1.3) 4 (0.5) 10 (3.6)
81 Low 14 (1.3) 9 (1.1) 5 (1.8)
82 High 11 (1.0) 6 (0.7) 5 (1.8)
33 High 7 (0.6) 0 (0.0) 7 (2.5)
72 Low 7 (0.6) 6 (0.7) 1 (0.4)
11 Low 3 (0.3) 2 (0.2) 1 (0.4)
26 High 1 (0.1) 0 (0.0) 1 (0.4)
71 Low 1 (0.1) 1 (0.1) 0 (0.0)
IS39 High 1 (0.1) 0 (0.0) 1 (0.4)
64 High 0 (0.0) 0 (0.0) 0 (0.0)
69 High 0 (0.0) 0 (0.0) 0 (0.0)
Note. Table reports n (%). HPV = human papillomavirus, CARE = Community
Awareness Resources Education.
aHigh- and low-risk classification scheme is the same as a recent national study
that analyzed data from the National Health and Nutrition Examination Survey
(NHANES) [4].
doi:10.1371/journal.pone.0074276.t003
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Table 4. Detection of any HPV type among women from the CARE Project (n = 1116).
No. of women with any HPV
type detected/total no. of







18–26 268/462 (58.0) 3.02 (2.21–4.13)** 2.09 (1.26–3.50)*
27–39 110/293 (37.5) 1.40 (0.99–1.97) 1.00 (0.65–1.56)
40 or older 102/358 (28.5) ref. ref.
Race/ethnicity
Non-Hispanic white 439/1038 (42.3) ref. --
Other 37/67 (55.2) 1.37 (0.82–2.31) --
Marital status
Never married 209/362 (57.7) 2.79 (2.08–3.74)** 1.26 (0.80–1.99)
Divorced/widowed/separated 96/199 (48.2) 2.02 (1.44–2.85)** 1.10 (0.69–1.76)
Married/member of a couple 159/526 (30.2) ref. ref.
Education
Less than a high school degree 66/131 (50.4) 1.37 (0.92–2.02) --
High school degree 189/408 (46.3) 1.24 (0.95–1.62) --
More than a high school degree 223/572 (39.0) ref. --
Annual household income
$20,000 or less 253/477 (53.0) 3.32 (2.14–5.17)** 1.66 (0.97–2.84)
$20,001–$50,000 110/297 (37.0) 1.88 (1.20–2.96)* 1.11 (0.66–1.87)
More than $50,000 37/166 (22.3) ref. ref.
Health Characteristics
Smoking status
Never smoker 155/471 (32.9) ref. ref.
Former smoker 63/167 (37.7) 1.24 (0.85–1.81) 0.98 (0.60–1.61)
Current smoker 259/469 (55.2) 2.19 (1.66–2.88)** 1.86 (1.26–2.73)*
Ever been pregnant
No 164/311 (52.7) ref. ref.
Yes 310/788 (39.3) 0.62 (0.47–0.81)** 0.80 (0.50–1.27)
Pap test within the last 3 years
No 65/161 (40.4) 0.85 (0.60–1.20) --
Yes 413/949 (43.5) ref. --
Ever have prior abnormal Pap test
No 230/620 (37.1) ref. ref.
Yes 249/486 (51.2) 1.74 (1.35–2.23)** 1.34 (0.95–1.90)
Pap test result upon entry into CARE Project
Normal (control) 269/838 (32.1) ref. ref.
Abnormal (case) 212/278 (76.3) 6.81 (4.92–9.41)** 5.59 (3.73–8.37)**
Ever told they had HPV infection (venereal warts, condylomas, or
a papillomavirus infection)
No 401/974 (41.2) ref. ref.
Yes 73/126 (57.9) 1.99 (1.35–2.93)** 1.21 (0.73–2.00)
Age at first sexual intercourse
15 or younger 174/350 (49.7) 1.35 (1.04–1.76)* 0.81 (0.56–1.16)
16 or older 299/736 (40.6) ref. ref.
Number of male sexual partners during lifetime
4 or fewer 136/458 (29.7) ref. ref.
5 or more 314/561 (56.0) 2.87 (2.19–3.75)** 2.28 (1.56–3.33)**
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test upon entry into the CARE Project (OR = 5.59, 95% CI: 3.73–
8.37), at least five male sexual partners during their lifetime
(OR = 2.28, 95% CI: 1.56–3.33), or multiple male sexual partners
during the last year (OR = 1.98, 95% CI: 1.25–3.14).
Multivariable correlates of high-risk HPV detection were highly
similar to those for detection of any HPV type (Table 5). Detection
of a high-risk HPV type was more common among women ages
18-26 compared to women ages 40 or older (OR = 3.25, 95% CI:
1.86–5.66) and among current smokers compared to never
smokers (OR = 1.52, 95% CI: 1.01–2.30). Detection was also
more common among women with a previous abnormal Pap test
(OR = 1.51, 95% CI: 1.04–2.21), an abnormal Pap test upon entry
into the CARE Project (OR = 6.26, 95% CI: 4.19–9.37), at least
five male sexual partners during their lifetime (OR = 2.57, 95%
CI: 1.69–3.92), or multiple male sexual partners during the last
year (OR = 1.70, 95% CI: 1.07–2.69).
Discussion
Appalachia is a geographic area with high cervical cancer
incidence and mortality rates [8–10], yet the prevalence of genital
HPV among Appalachian women is not known. Determining this
prevalence is necessary to better understand the existing cervical
cancer disparities among women from Appalachia. We detected at
least one HPV type in over 40% of women, and detection of high-
risk HPV was more common than detection of low-risk HPV.
When our data are compared to HPV prevalence estimates among
non-Hispanic white women from the NHANES [4](since our
study sample was predominantly non-Hispanic white), we believe
our findings potentially shed new light on current cervical cancer
disparities (Table 2). Appalachian women from our study were
similar to non-Hispanic white women from the NHANES in terms
of the prevalence of any HPV type (43.1% [95% CI: 40.2%–
46.0%] vs. 39.2% [95% CI: 37.0%–41.4%] [4]) and low-risk HPV
(23.4% [95% CI: 20.9%–25.9%] vs. 26.1% [95% CI: 24.0–28.2]
[4]). However, the prevalence of high-risk HPV was higher among
Appalachian women (33.5% [95% CI: 30.7%–36.3%] vs. 26.9%
[95% CI: 24.7–29.1] [4]). This pattern of findings is important
because high-risk HPV types have a causal role in almost all
cervical cancers [21], and the higher prevalence of these HPV
types among Appalachian women may be a key contributing
factor to the higher cervical cancer incidence rates observed
among these women.
The design of our study should be considered when interpreting
these results. Our data are from a case-control study that was
designed to identify determinants of abnormal cervical cytology, so
one-fourth of our sample had an abnormal Pap test upon study
entry. This is higher than the prevalence of abnormal cytology
among women from studies that were not case-control studies (up
to 14% [22]). The prevalence of HPV in our study may therefore
differ from what would be obtained from a random sample of
Appalachian women. Indeed, HPV detection was more common
among the cases in our study compared to controls. We do not
believe, however, that study design solely accounts for the pattern
of findings observed in the current study. Although future research
is needed to confirm the findings from this study, our data provide
valuable initial insight into the prevalence of HPV among
Appalachian women and suggest that high-risk HPV infections
may be more prevalent among women from this region, which
may help explain the existing cervical cancer disparities in
Appalachia.
Detection of any HPV type and detection of a high-risk HPV
type were more common among women ages 18–26 compared to
older women in our study. This pattern is similar to what has been
found in past studies, where HPV was more prevalent among
younger women [4]. Importantly, a vaccine-preventable HPV type
was detected in over 20% of women ages 18–26, which is higher
than the prevalence of these HPV types among women of similar
ages from the NHANES (8.8% [23]). These results suggest that
Appalachian females could benefit substantially from HPV
vaccine. HPV vaccine is available in most healthcare facilities in
Appalachia [24], and adults in the Appalachian region are
accepting of the vaccine for females [25,26]. However, HPV
vaccine uptake among adolescent females varies greatly within the
Appalachian region and is especially lacking in regions of
Appalachia with existing cervical cancer disparities [27,28]. Since
HPV vaccine uptake tends to be even lower among young adult
females compared to adolescent females [29,30], it is likely that
most young adult women in Appalachia remain unvaccinated.
Our data begin to demonstrate the potential impact that HPV
Table 4. Cont.
No. of women with any HPV
type detected/total no. of





Number of male sexual partners during last year
0–1 307/851 (36.1) ref. ref.
2 or more 155/220 (70.5) 3.84 (2.74–5.38)** 1.98 (1.25–3.14)*
Any male sexual partners with history of STI
No/don’t know 405/952 (42.5) ref. --
Yes 56/115 (48.7) 1.13 (0.76–1.68) --
Number of female sexual partners
during lifetime
0 441/1042 (42.3) ref. ref.
1 or more 35/53 (66.0) 2.30 (1.25–4.21)* 0.79 (0.36–1.76)
Note. Totals may be less than stated sample size due to missing data. The multivariable model included data on 814 women due to missing data on correlates. The
multivariable model did not include variables with dashes (--). HPV = human papillomavirus, CARE = Community Awareness Resources Education, OR = odds ratio, CI
= confidence interval, ref. = referent group, STI = sexually transmitted infection.
*p,0.05, **p,0.001.
doi:10.1371/journal.pone.0074276.t004
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Table 5. Detection of high-risk HPV among women from the CARE Project (n = 1116).a
No. of women with high-risk
HPV type detected/total no.







18–26 227/462 (49.1) 4.56 (3.25–6.40)** 3.25 (1.86–5.66)**
27–39 85/293 (29.0) 1.97 (1.34–2.89)** 1.31 (0.80–2.16)
40 or older 61/358 (17.0) ref. ref.
Race/ethnicity
Non-Hispanic white 341/1038 (32.9) ref. --
Other 28/67 (41.8) 1.27 (0.75–2.14) --
Marital status
Never married 172/362 (47.5) 2.80 (2.07–3.78)** 1.17 (0.73–1.88)
Divorced/widowed/separated 66/199 (33.2) 1.59 (1.10–2.31)* 0.97 (0.58–1.63)
Married/member of a couple 121/526 (23.0) ref. ref.
Education
Less than a high school degree 50/131 (38.2) 1.25 (0.83–1.88) --
High school degree 147/408 (36.0) 1.20 (0.91–1.59) --
More than a high school degree 174/572 (30.4) ref. --
Annual household income
$20,000 or less 190/477 (39.8) 3.17 (1.97–5.10)** 1.33 (0.73–2.43)
$20,001–$50,000 91/297 (30.6) 2.24 (1.37–3.66)* 1.21 (0.67–2.19)
More than $50,000 26/166 (15.7) ref. ref.
Health Characteristics
Smoking status
Never smoker 122/471 (25.9) ref. ref.
Former smoker 43/167 (25.8) 0.99 (0.66–1.51) 0.76 (0.44–1.34)
Current smoker 207/469 (44.1) 2.05 (1.54–2.73)** 1.52 (1.01–2.30)*
Ever been pregnant
No 139/311 (44.7) ref. ref.
Yes 231/788 (29.3) 0.54 (0.41–0.71)** 0.75 (0.46–1.21)
Pap test within the last 3 years
No 51/161 (31.7) 0.88 (0.60–1.27) --
Yes 321/949 (33.8) ref. --
Ever have prior abnormal Pap test
No 174/620 (28.1) ref. ref.
Yes 198/486 (40.7) 1.72 (1.33–2.23)** 1.51 (1.04–2.21)*
Pap test result upon entry into CARE Project
Normal (control) 180/838 (21.5) ref. ref.
Abnormal (case) 194/278 (69.8) 8.35 (6.10–11.43)** 6.26 (4.19–9.37)**
Ever told they had HPV infection (venereal warts, condylomas,
or a papillomavirus infection)
No 314/974 (32.2) ref. ref.
Yes 57/126 (45.2) 1.73 (1.18–2.53)* 0.94 (0.55–1.61)
Age at first sexual intercourse
15 or younger 141/350 (40.3) 1.42 (1.08–1.87)* 0.95 (0.64–1.40)
16 or older 228/736 (31.0) ref. ref.
Number of male sexual partners during lifetime
4 or fewer 101/458 (22.1) ref. ref.
5 or more 253/561 (45.1) 2.77 (2.09–3.68)** 2.57 (1.69–3.92)**
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vaccination can have among these young women, and future
efforts are needed to ensure that HPV vaccine uptake is occurring
among this age group.
Detection of any HPV type and detection of a high-risk HPV
type was more common among women who were current smokers
or reported a higher number of sexual partners (both lifetime and
recent partners). These findings coincide with those from previous
studies examining HPV prevalence among women in the U.S.
[4,31]. Risky sexual behavior, such as a higher number of sexual
partners, increases the risk of exposure to HPV [32], and smoking
may prolong the duration of HPV infections and decrease the
chance of clearing infections [13]. These issues could be
particularly relevant when examining HPV prevalence among
Appalachian women, as data indicate that risky sexual behavior is
common among these women [11] and smoking rates are higher
among Appalachian residents compared to non-Appalachian
residents [12]. Thus, risky sexual behavior and smoking are likely
playing an important role in Appalachian women acquiring an
HPV infection and the subsequent risk of developing an HPV-
related disease. Knowledge about HPV and cervical cancer risk
factors is lacking among Appalachian women [26,33], so
educational programs are needed to increase these women’s
awareness of and knowledge about these issues.
Study strengths include a large sample size and inclusion of
women from throughout the Appalachian Ohio region. Our study
also has several limitations. We were not able to examine the
persistence or clearance of HPV infection. The study included
women presenting to health clinics, which may limit the
generalizability of findings since these women may have greater
access to Pap testing compared to others from Appalachian Ohio.
This may be important since Pap testing within recommended
guidelines tends to be less common among women from
Appalachian Ohio compared to women from non-Appalachian
Ohio [34]. It is also possible that some women in our study were
being seen at the health clinics for reasons related to HPV
infection. Similar to the NHANES [4], participants self-reported
behavioral data (e.g., sexual behavior and smoking status), which
may have resulted in some misclassification. HPV vaccination data
were available on less than 20% of women in our study, which did
not allow us to account for this variable in analyses. However, less
than 6% of women for whom vaccination data were available had
received any doses of HPV vaccine, suggesting the impact of
vaccination on our results was likely minimal.
HPV was prevalent among Appalachian women and many had
a high-risk HPV type detected. These data not only provide the
first insight into the prevalence of HPV among Appalachian
women but may also help explain the existing cervical cancer
disparities within this geographic region. Results can help inform
future cervical cancer prevention efforts in Appalachia, specifically
those designed to increase HPV vaccine uptake or women’s
awareness of and knowledge about HPV and cervical cancer.
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